RNA, U4 small nuclear 60, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-60P profile across patient tissues and cancer cell-line models. RNU4-60P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, RNU4-60P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, RNU4-60P RNA expression shows 5,799 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, and STAD as cancer lineages where RNU4-60P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-60P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-60P survival associations across molecular data types. RNU4-60P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-60P RNA expression–survival associations across cancer types. High RNU4-60P expression shows unfavorable associations in READ, LIHC, PAAD, SKCM and LUSC, but favorable associations in SARC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for RNU4-60P RNA expression.
This table summarizes RNU4-60P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-60P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-60P shows lower tumor expression in ESCA and higher tumor expression in STAD and LUSC. The STAD box plot shows higher RNU4-60P RNA expression in tumor versus normal tissue (log2 FC = +0.198, t-test p = .035).
This table shows molecular features associated with RNU4-60P in patient tissues and cancer cell lines. In patient samples, RNU4-60P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
